Ocera Therapeutics Inc (OCRX) 3.86 $OCRX
Ocera Therapeutics to Report Pipeline Progress and First Quarter 2015 Financial Results
GlobeNewswire - Wed Apr 22, 3:43PM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its first quarter 2015 financial results on Thursday, April 30, 2015 at approximately 8:00 a.m. Eastern Time. In conjunction with this announcement, Ocera will host a conference call and webcast on Thursday, April 30, 2015 at 10:00 a.m. Eastern Time to both review the financial results and provide updates on its clinical development program.
OCRX: 3.86 (-0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 11:45AM CDT
KRNT: 14.99 (unch), ARCW: 7.06 (-0.57), TOF: 4.12 (-0.03), SSN: 1.54 (-0.02), CNAT: 6.31 (-0.15), NYMX: 1.32 (-0.08), SEAC: 7.23 (+0.25), UACL: 22.34 (+0.42), WBAI: 16.75 (-0.46), LBIX: 3.60 (+0.22), CARB: 11.14 (-0.07), EBIO: 10.32 (+0.22), CTSO: 7.13 (-0.06), AKER: 4.55 (+0.05), SQBG: 13.46 (-0.54), TRIB: 17.17 (-0.17), OCRX: 3.86 (-0.07), TCPI: 3.85 (-0.13), TRUE: 15.72 (-0.26), FHCO: 3.19 (+0.02)
Ocera's lead product clinical trial completion date late 2016
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 7:39PM CDT
OCRX: 3.86 (-0.07)
Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy
GlobeNewswire - Wed Apr 01, 4:03PM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced successful completion of a planned interim analysis of its STOP-HE study, a double-blind placebo-controlled study of OCR-002 in patients with acute hepatic encephalopathy (HE). The study's independent Data Monitoring Committee (DMC) reported that the trial is not futile and no drug-related safety signals have been observed in the study. Based on the DMC's recommendation, Ocera will continue the STOP-HE study and will increase target enrollment from 140 patients to approximately 230 patients. The Company remains blinded to data reviewed by the DMC in the interim analysis.
OCRX: 3.86 (-0.07)
Ocera's (OCRX) CEO Linda Grais on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 11, 8:46PM CDT
OCRX: 3.86 (-0.07)
Ocera reports 4Q loss
Automated Insights - Wed Mar 11, 3:51PM CDT
PALO ALTO, Calif. (AP) _ Ocera Therapeutics Inc. (OCRX) on Wednesday reported a loss of $5.5 million in its fourth quarter.
OCRX: 3.86 (-0.07)
Ocera Therapeutics beats by $0.17, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:06PM CDT
OCRX: 3.86 (-0.07)
Ocera Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Wed Mar 11, 3:01PM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced updates to its clinical development programs and reported financial results and other business highlights for the quarter and year ended December 31, 2014.
OCRX: 3.86 (-0.07)
Ocera Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Mon Mar 02, 3:05PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its fourth quarter and full year 2014 financial results and other information on Wednesday, March 11, 2015 at approximately 4:00 p.m. Eastern Time. In conjunction with this announcement, Ocera will host a conference call on Wednesday, March 11, 2015 at 4:30 p.m. Eastern Time.
OCRX: 3.86 (-0.07)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 8:12AM CST
TTPH: 39.96 (-0.50), WLL: 36.12 (+1.16), EXXI: 3.87 (-0.13), NLST: 0.57 (+0.01), OIBR: 2.07 (-0.04), ASTI: 1.07 (+0.04), NVGN: 7.40 (-0.30), LIVE: 3.19 (-0.07), GTE: 3.55 (+0.03), PCLN: 1,212.90 (+18.64), GENE: 4.88 (-0.05), PWE: 2.38 (+0.03), GDP: 3.58 (-0.10), CLRX: 0.95 (unch), QTWW: 2.86 (-0.03), BJRI: 50.54 (-1.00), EOG: 97.70 (+1.11), VGGL: 2.77 (+0.27), OCRX: 3.86 (-0.07), CDE: 5.36 (-0.14), OAS: 16.47 (-0.36), EXEL: 3.12 (+0.05)
Ocera sinks on mixed clinical trial results
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 8:06AM CST
OCRX: 3.86 (-0.07)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 4:38PM CST
BJRI: 50.54 (-1.00), UWTI: 3.15 (-0.06), OCRX: 3.86 (-0.07), CSLT: 7.85 (+0.36), SIX: 49.97 (+1.37), KEYW: 9.97 (+0.06), CYBE: 10.69 (unch), SCO: 62.54 (+0.43), DWTI: 79.10 (+1.20), YNDX: 20.70 (+0.26)
Ocera Announces Preliminary Topline Results From Phase 2a Investigator-Sponsored Study of OCR-002
GlobeNewswire - Wed Feb 18, 3:05PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX) today announced preliminary topline results from a Phase 2a investigator-sponsored study evaluating the company's drug candidate OCR-002 (ornithine phenylacetate) versus placebo in patients with upper gastrointestinal bleeding (UGIB) associated with liver cirrhosis. The data demonstrated a favorable safety profile for OCR-002 and that the drug candidate was well tolerated. The data also supported OCR-002's ability to reduce ammonia levels, elevated levels of which correlate with certain severe and life-threatening liver disorders. In the study, an acute ammonia lowering effect in plasma, as well as higher urinary excretion of ammonia, was observed in patients treated with OCR-002 compared to placebo. The differences in plasma ammonia levels between treatment arms did not reach statistical significance, but the differences in urinary excretion of ammonia were statistically significant.
OCRX: 3.86 (-0.07)
Can the Rally in Ocera Therapeutics (OCRX) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 8:29AM CST
Can the Rally in Ocera Therapeutics (OCRX) Shares Continue?
OCRX: 3.86 (-0.07)
The Stage Is Set For Investors To Realize Huge Gains With Ocera Therapeutics
BioCourse AP - at Seeking Alpha - Tue Jan 06, 9:23AM CST
OCRX: 3.86 (-0.07)
Nasdaq stocks posting largest percentage increases
AP - Wed Dec 31, 6:59PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
RESN: 3.77 (-0.06), CYTK: 7.29 (-0.09), SIGM: 8.36 (+0.29), SIBC: 21.04 (-0.18), IDSA: 3.84 (-0.18), OCRX: 3.86 (-0.07), DJCO: 185.08 (+0.06)
Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer
GlobeNewswire - Wed Dec 03, 7:10AM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the appointment of Michael Byrnes as chief financial officer.
OCRX: 3.86 (-0.07)
Ocera Therapeutics (OCRX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:48AM CST
Ocera Therapeutics (OCRX) Shares March Higher, Can It Continue?
OCRX: 3.86 (-0.07)
Ocera Therapeutics to Report Pipeline Progress and First Quarter 2015 Financial Results
GlobeNewswire - Wed Apr 22, 3:43PM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its first quarter 2015 financial results on Thursday, April 30, 2015 at approximately 8:00 a.m. Eastern Time. In conjunction with this announcement, Ocera will host a conference call and webcast on Thursday, April 30, 2015 at 10:00 a.m. Eastern Time to both review the financial results and provide updates on its clinical development program.
OCRX: 3.86 (-0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 11:45AM CDT
KRNT: 14.99 (unch), ARCW: 7.06 (-0.57), TOF: 4.12 (-0.03), SSN: 1.54 (-0.02), CNAT: 6.31 (-0.15), NYMX: 1.32 (-0.08), SEAC: 7.23 (+0.25), UACL: 22.34 (+0.42), WBAI: 16.75 (-0.46), LBIX: 3.60 (+0.22), CARB: 11.14 (-0.07), EBIO: 10.32 (+0.22), CTSO: 7.13 (-0.06), AKER: 4.55 (+0.05), SQBG: 13.46 (-0.54), TRIB: 17.17 (-0.17), OCRX: 3.86 (-0.07), TCPI: 3.85 (-0.13), TRUE: 15.72 (-0.26), FHCO: 3.19 (+0.02)
Ocera's lead product clinical trial completion date late 2016
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 7:39PM CDT
OCRX: 3.86 (-0.07)
Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy
GlobeNewswire - Wed Apr 01, 4:03PM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced successful completion of a planned interim analysis of its STOP-HE study, a double-blind placebo-controlled study of OCR-002 in patients with acute hepatic encephalopathy (HE). The study's independent Data Monitoring Committee (DMC) reported that the trial is not futile and no drug-related safety signals have been observed in the study. Based on the DMC's recommendation, Ocera will continue the STOP-HE study and will increase target enrollment from 140 patients to approximately 230 patients. The Company remains blinded to data reviewed by the DMC in the interim analysis.
OCRX: 3.86 (-0.07)
Ocera's (OCRX) CEO Linda Grais on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 11, 8:46PM CDT
OCRX: 3.86 (-0.07)
Ocera reports 4Q loss
Automated Insights - Wed Mar 11, 3:51PM CDT
PALO ALTO, Calif. (AP) _ Ocera Therapeutics Inc. (OCRX) on Wednesday reported a loss of $5.5 million in its fourth quarter.
OCRX: 3.86 (-0.07)
Ocera Therapeutics beats by $0.17, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:06PM CDT
OCRX: 3.86 (-0.07)
Ocera Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Wed Mar 11, 3:01PM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced updates to its clinical development programs and reported financial results and other business highlights for the quarter and year ended December 31, 2014.
OCRX: 3.86 (-0.07)
Ocera Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Mon Mar 02, 3:05PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its fourth quarter and full year 2014 financial results and other information on Wednesday, March 11, 2015 at approximately 4:00 p.m. Eastern Time. In conjunction with this announcement, Ocera will host a conference call on Wednesday, March 11, 2015 at 4:30 p.m. Eastern Time.
OCRX: 3.86 (-0.07)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 8:12AM CST
TTPH: 39.96 (-0.50), WLL: 36.12 (+1.16), EXXI: 3.87 (-0.13), NLST: 0.57 (+0.01), OIBR: 2.07 (-0.04), ASTI: 1.07 (+0.04), NVGN: 7.40 (-0.30), LIVE: 3.19 (-0.07), GTE: 3.55 (+0.03), PCLN: 1,212.90 (+18.64), GENE: 4.88 (-0.05), PWE: 2.38 (+0.03), GDP: 3.58 (-0.10), CLRX: 0.95 (unch), QTWW: 2.86 (-0.03), BJRI: 50.54 (-1.00), EOG: 97.70 (+1.11), VGGL: 2.77 (+0.27), OCRX: 3.86 (-0.07), CDE: 5.36 (-0.14), OAS: 16.47 (-0.36), EXEL: 3.12 (+0.05)
Ocera sinks on mixed clinical trial results
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 8:06AM CST
OCRX: 3.86 (-0.07)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 4:38PM CST
BJRI: 50.54 (-1.00), UWTI: 3.15 (-0.06), OCRX: 3.86 (-0.07), CSLT: 7.85 (+0.36), SIX: 49.97 (+1.37), KEYW: 9.97 (+0.06), CYBE: 10.69 (unch), SCO: 62.54 (+0.43), DWTI: 79.10 (+1.20), YNDX: 20.70 (+0.26)
Ocera Announces Preliminary Topline Results From Phase 2a Investigator-Sponsored Study of OCR-002
GlobeNewswire - Wed Feb 18, 3:05PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX) today announced preliminary topline results from a Phase 2a investigator-sponsored study evaluating the company's drug candidate OCR-002 (ornithine phenylacetate) versus placebo in patients with upper gastrointestinal bleeding (UGIB) associated with liver cirrhosis. The data demonstrated a favorable safety profile for OCR-002 and that the drug candidate was well tolerated. The data also supported OCR-002's ability to reduce ammonia levels, elevated levels of which correlate with certain severe and life-threatening liver disorders. In the study, an acute ammonia lowering effect in plasma, as well as higher urinary excretion of ammonia, was observed in patients treated with OCR-002 compared to placebo. The differences in plasma ammonia levels between treatment arms did not reach statistical significance, but the differences in urinary excretion of ammonia were statistically significant.
OCRX: 3.86 (-0.07)
Can the Rally in Ocera Therapeutics (OCRX) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 8:29AM CST
Can the Rally in Ocera Therapeutics (OCRX) Shares Continue?
OCRX: 3.86 (-0.07)
The Stage Is Set For Investors To Realize Huge Gains With Ocera Therapeutics
BioCourse AP - at Seeking Alpha - Tue Jan 06, 9:23AM CST
OCRX: 3.86 (-0.07)
Nasdaq stocks posting largest percentage increases
AP - Wed Dec 31, 6:59PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
RESN: 3.77 (-0.06), CYTK: 7.29 (-0.09), SIGM: 8.36 (+0.29), SIBC: 21.04 (-0.18), IDSA: 3.84 (-0.18), OCRX: 3.86 (-0.07), DJCO: 185.08 (+0.06)
Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer
GlobeNewswire - Wed Dec 03, 7:10AM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the appointment of Michael Byrnes as chief financial officer.
OCRX: 3.86 (-0.07)
Ocera Therapeutics (OCRX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:48AM CST
Ocera Therapeutics (OCRX) Shares March Higher, Can It Continue?
OCRX: 3.86 (-0.07)
